title: A randomized controlled safety and acceptability trial of dextrin sulphate vaginal microbicide gel in sexually active women in Uganda.
abstract: OBJECTIVE
  To assess the safety of dextrin sulphate (DS) gel compared to placebo gel in terms of local and systemic adverse events, and to determine the acceptability of dextrin sulphate gel.
  
  
  METHODS
  A 4-week randomized trial of DS intra-vaginal gel, partially blinded, with placebo and observation control arms. Participants were randomized to use DS gel twice daily, placebo gel twice daily, DS gel pre-sex, or into an observation only arm.
  
  
  METHODS
  Sexually active women were recruited from post natal and HIV clinics at Nsambya Hospital, Kampala, Uganda. Screening, enrollment and follow-up visits took place every 1 or 2 weeks over an 8-week period and consisted of questionnaire interviews, colposcopy examinations, sexually transmitted infection screen and routine laboratory testing.
  
  
  RESULTS
  Out of a total of 172 women screened, 109 were randomized to use DS gel twice daily (65 women), placebo gel twice daily (15 women), DS gel pre-sex (nine women) or into an observation only arm (20 women). Two individuals had abnormal colposcopy findings in the DS twice daily gel use arm. Vaginal bleeding was reported as frequently by participants in the active gel arm as by participants in the placebo and observation only arms. No clinically significant difference was observed between arms in terms of vaginal flora, Candida, haemoglobin, white cell count, platelets, thrombin time, activated partial thromboplastin time, creatinine and aspartate aminotransferase results after 4 weeks of gel use. DS gel appeared to be acceptable to over 95% of the users.
  
  
  CONCLUSIONS
  Results show a satisfactory safety and acceptability profile of dextrin sulphate gel.
authors.affiliation: Medical Research Council Programme on AIDS in Uganda/Uganda Virus Research Institute, Entebbe, Uganda. jmb@ctu.mrc.ac.uk
authors.forename: Julie M
authors.initials: JM
authors.lastname: Bakobaki
authors.forename: Charles J
authors.initials: CJ
authors.lastname: Lacey
authors.forename: Michael I
authors.initials: MI
authors.lastname: Bukenya
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Nunn
authors.forename: Sheena
authors.initials: S
authors.lastname: McCormack
authors.forename: Romano N
authors.initials: RN
authors.lastname: Byaruhanga
authors.forename: Pius
authors.initials: P
authors.lastname: Okong
authors.forename: Stella W
authors.initials: SW
authors.lastname: Namukwaya
authors.forename: Heiner
authors.initials: H
authors.lastname: Grosskurth
authors.forename: James Ag
authors.initials: JA
authors.lastname: Whitworth
mesh_terms: D000282:Administration, Intravaginal; D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003912:Dextrins / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D017060:Patient Satisfaction; D012449:Safety; D012725:Sexual Behavior; D012749:Sexually Transmitted Diseases / Q000517:prevention & control*; D014454:Uganda; D014622:Vaginal Creams, Foams, and Jellies / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000890:Anti-Infective Agents; D003912:Dextrins; D014622:Vaginal Creams, Foams, and Jellies